Lexicon expects delay in FDA feedback on additional data for its diabetes drug

Lexicon Pharmaceuticals LXRX said on Monday the U.S. Food and Drug Administration requires more time to review the company's previously submitted additional data on its experimental drug, Zynquista, for patients with type 1 diabetes.